ArticleFrontiers in oncology2026

Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study.

Zhi-Ran Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.